Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Confirmatory study of OPC-12759 ophthalmic solution in dry eye
jRCT2080221875Phase 3Completed
- Sponsor
- Otsuka Holdings
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rebamipide in dry eye syndrome (DED) (3 arms), sponsored by Otsuka Holdings. Primary endpoint: Efficacy of 2% rebamipide ophthalmic solution versus placebo and suspension. Started Aug 2012; status: completed.
02
Drugs
rebamipide
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on jRCT2080221875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221875.